ALAmir Lass

Amir Lass

*This is an algorithmically generated author record based on publicly available information.

Amir Lass has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States

    by Sigal Kaplan, Monica L. Bertoia, Florence T. Wang, Li Zhou, Amir Lass, Alison Evans, Sandeep Dhanda, Debabrata Roy, John D. Seeger


  • Inequalities in assisted reproduction technology utilisation between the G20 countries

    by Amir Lass, Geffen Lass

    Large global inequalities in assisted reproduction technology (ART) utilisation have existed ever since the introduction of ART. The reasons for these inequalities are multifactorial and include national wealth and affordability, pronatalist policies, regulatory differences in provision, and sociocultural components such as racial, gender and educational inequalities. Examining ART utilisation across the largest world economies (G20 countries) in 2016 (the most recent year with publically available data) reveals significant inequality, which is highly correlated to gross domestic product per capita, a measure of national wealth, and to provision of government funding and/or insurance coverage for in vitro fertilisation and intracytoplasmic sperm injection. A strong negative correlation with the Gender Inequality Index is also noted. The gap in ART utilisation rate will only begin to close once the majority of nations introduce more affordable ART treatment, instigate pronatalist policies, and implement changes in education, attitudes and behaviours to minimise racial and gender inequalities; however, achieving all of these changes may be a very difficult target to attain for many poorer economies, regardless of their size.


  • P–592 Safety and effectiveness of follitropin alfa biosimilar to originator follitropin alfa in real-world clinical practice: A Multinational Comparative, Prospective Cohort Study

    by S Kaplan, R Levy-Toledano, M Davies, D Roy, C Howles, A Lass

    Study question: Are safety and effectiveness of Ovaleap® (follitropin alfa), and Gonal-f®, comparable in one treatment cycle of ART in routine clinical practice? Summary answer: Safety in terms of incidence proportions of OHSS and OHSS severity, as well as pregnancy and live birth rates, were similar between Ovaleap® and Gonal-f®. What is known already: Ovaleap® (Theramex), a r-hFSH, is a biosimilar medicinal product to Gonal-f® (Merck). As a biosimilar, it went through a rigorous series of physio-chemical, in vitro, in vivo tests and confirmatory Phase I and III studies, to demonstrate similarity/equivalence in quality, safety and efficacy to the reference medicinal product, per the European Medicines Agency (EMA) guidelines. Ovaleap® was approved by the EMA in 2013 for use at the same dose and for the same therapeutic indications as Gonal-f®. Further outcome data from a broader patient population on safety and live birth outcomes provides clinically important insights on newly introduced FSH medicines. Study design, size, duration: SOFIA (Safety of Ovaleap® Follitropin alfa in Infertile women undergoing superovulation for Assisted reproductive technologies) was a multi-national, comparative, non-interventional, prospective cohort study. The study was performed at 56 centers specializing in ART from six European countries, (Belgium, France, Germany, Italy, Spain, and the United Kingdom) from January 2017 to September 2019 and comprised of 817 infertile women undergoing controlled ovarian hyperstimulation in one treatment cycle for ART Participants/materials, setting, methods: The study population comprised of infertile women undergoing controlled ovarian hyperstimulation for ART, who were administered Ovaleap® or Gonal-f® and were naïve to any FSH containing products. Eligible patients were enrolled at a ratio of approximately 1:1, both within and between countries. They were followed up to 30 days after the last FSH dose administration. Women who had a confirmed clinical pregnancy were followed until the end of the pregnancy or until delivery. Main results and the role of chance: A total of 408 and 409 women who were administered Ovaleap® or Gonal-f®, respectively, were eligible for analysis. A total of 382 patients (94%) in the Ovaleap® and 390 patients (95%) in the Gonal-f® cohort completed FSH treatment (up to oocyte maturation triggering), respectively. The two cohorts were generally similar with regard to demographic and baseline characteristics. The incidence proportion of OHSS was 5.1% (95% CI: 3.4, 7.7) in the Ovaleap® and 3.2% (95% CI: 1.9, 5.4) in the Gonal-f® cohort. This difference in OHSS incidence proportion between the two cohorts was not statistically significant neither before (p = 0.159) nor after univariate adjustment for each potential confounder (p > 0.05). The incidence proportion of OHSS severity grades was similar in the two treatment groups (3.4% versus 2.0% for Grade I, 1.2% versus 1.0% Grade II, and 0.5% versus 0.2% Grade III, in the Ovaleap® and Gonal-f® cohorts, respectively) and without a significant statistical difference (p = 0.865, for each grade). Among patients who had embryo transfer, clinical pregnancy rates were 33% and 31%, live birth rates 27% and 26% in the Ovaleap® and Gonal-f® cohorts, respectively. Limitations, reasons for caution: Since treatment was non-randomised, the study may have been susceptible to selection bias. This was addressed at both the design stage, by balancing recruitment to a 1:1 ratio for Ovaleap® and Gonal-f® treatments, and also at the analysis stage in which, a univariate analysis was performed. Wider implications of the findings: Findings from this first large European prospective comparative real-world SOFIA study demonstrated that effectiveness (pregnancy and delivery rates) and safety (risk and severity of OHSS), were similar between Ovaleap®and Gonal-f® treatments. Ovaleap, a biosimilar r-hFSH is therefore a suitable option for follicular stimulation in routine clinical practice. Trial registration number: EUPAS17328

  • Open Access

    Is there a correlation between total fertility rate, utilization of assisted reproduction technology, and national wealth in Europe?

    by Amir Lass, Geffen Lass

    To explore the relationships between total fertility rate (TFR), utilization of assisted reproduction technology (ART), and gross domestic product (GDP) per capita in Europe. Analysis of total ART cycles obtained from the latest European IVF-Monitoring Consortium (EIM) report for 2016. TFR, GDP and population size for that year were found in relevant World Bank data documents. In addition, this study compared two subgroups in Europe: developed economies and economies in transition, as defined by the UN. Pearson Correlations were calculated using Sigmaplot for utilization, GDP and TFR Forty countries were included in the 2016 EIM report. The mean utilization rate was 1,391 cycles per million population (C/M) (range = 162−3156) and mean TFR was 1.61 (range = 1.26−2.73). Mean GDP was $35,072 per capita (range = $10,610–$110,650). There was no correlation between TFR and utilization or GDP, however there was a significant positive correlation between GDP and utilization (correlation coefficient = 0.428; p = 0.00661). In the developed economies (n = 28) GDP and utilization were roughly 3-times higher than in the economies in transition (n = 11) ($42,710 vs $15,630; 1,674 vs 671), with a slightly lower TFR (1.58 vs 1.67). In the developed economies there was no correlation between GDP, TFR, and utilization, while in the economies in transition, the only significant correlation was GDP vs TFR (r = 0.69; p = 0.017). There is a strong correlation across Europe between GDP and utilization of ART. This correlation does not exist within the developed economies. In Europe the utilization of ART treatment is dependent on national wealth and not on the TFR in the country.


  • Correlation between gross domestic product, utilization of in vitro fertilization, and pregnancy success rate across the world

    by Amir Lass, Waleed Chaudary, Geffen Lass

    IVF is now a wide spread procedure globally, and currently 65 countries report annually all or part of their IVF/ICSI cycles, from which the International Committee Monitoring progress in Assisted Reproduction Technology (ICMART) published its report. There is considerable variation in the utilisation (number of cycles per population) globally. The objectives of this study were to assess whether utilisation is related to national wealth, presented as gross domestic product (GDP) and whether the GDP has any effect on success in IVF treatment, mainly delivery and clinical pregnancy rates. Our results demonstrated significant positive correlation between utilisation and GDP (CC =0.563, P = 0.00000194) and both utilisation and GDP have strong negative correlation to successful outcome of the treatment-clinical pregnancy rate (CC: -0.460, P = 0.00015; CC: -0.399, P = 0.0012; respectively) and delivery rates (cc=-0.396, p= 0.00484; cc=-0.3, p = 0.0179 respectively). Poor nations have less utilisation of IVF, probably due to limited affordability of treatment but reassuringly do not seem to have less success in the treatment. further research is required to fully understand the implications of these correlations and to better design national and international fertility policies.


  • RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain

    by Amir Lass, Stephen Maxwell Montgomery

    RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. Journal of Medical Economics. Accepted 13 January 2019.

  • Open Access

    The patient burden of opioid‐induced constipation: New insights from a large, multinational survey in five European countries

    by Viola Andresen, Vivek Banerji, Genevieve Hall, Amir Lass, Anton V Emmanuel

    Background: Despite its high prevalence, opioid‐induced constipation (OIC) remains under‐recognised and undertreated, and its true impact on wellbeing and quality of life (QoL) may be underestimated.Methods: A quantitative, questionnaire‐based international survey was conducted.Results: Weak‐opioid users appeared as bothered by constipation as strong‐opioid users (38% vs 40%, respectively; p = 0.40), despite it causing less‐severe physical symptoms and impact on QoL. Strong‐opioid users meeting Rome IV OIC criteria appeared to experience greater symptomatic and biopsychosocial burden from constipation than those not satisfying these criteria. Almost one‐fifth of respondents were dissatisfied with their current constipation treatment and around one‐third found balancing the need for adequate pain relief with constipation side effects challenging. Consequently, more than half failed to adhere to their prescribed treatment regimens, or resorted to suboptimal strategies, e.g. 40% reduced their opioid intake, to relieve constipation. Almost 60% of healthcare professionals did not adequately counsel patients about constipation as a common side effect of opioid use.Conclusions: Findings suggest that both weak‐ and strong‐opioid users suffer comparable bother and decreased QoL, Rome IV criteria can identify patients with more‐severe OIC, but may underdiagnose patients showing fewer symptoms, and increased education is needed to manage patients’ expectations and enable improved OIC self‐management.


  • Open Access

    Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms

    by Louise R Newson, Amir Lass

    The menopause is a normal life event for women, not an illness or a medical condition. However, the effects of the menopause often have a negative impact on women’s wellbeing and quality of life. Furthermore, the low oestrogen levels and other biological changes that occur in these women are also associated with an increased risk of cardiovascular disease, osteoporosis, diabetes, and dementia.